VMD-928 Tablet and Pembrolizumab (200 mg)
6 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cystic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 Tablet and Pembrolizumab (200 mg) for laryngeal diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 Tablet and Pembrolizumab (200 mg) for mesothelioma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 Tablet and Pembrolizumab (200 mg) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 Tablet and Pembrolizumab (200 mg) for tracheal diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |